Urinalysis: always obtain, consider separate workup if evidence of hematuria or UTI
PVR and urine culture: not required for uncomplicated patients
Other testing: CT/US, urodynamics, cystoscopy, and cytology are not required for uncomplicated patients
Considerations for men
Cause: often secondary to BPH/BOO, resulting in detrusor overactivity
Incontinence: much less prevalent (16% vs 55%)
Retention risk: < 3% with anticholinergics, but not recommended if flow rate < 5mL/s or PVR > 200mL
Post-outlet treatment: OAB resolution seen in 70%, can take up to 6-12mo to improve (keep on medications until this time)
References
AUA Core Curriculum
Gormley, E. Ann, et al. "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline." The Journal of urology 188.6S (2012): 2455-2463.
Heesakkers, J. and B. Blok. "Electrical Stimulation and Neuromodulation in Storage and Emptying Failure." Campbell-Walsh Urology 12 (2020).
Herschorn, Sender, et al. "Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)." BJU international 120.4 (2017): 562-575.
Reynolds, W. and J. Cohn. "Overactive Bladder." Campbell-Walsh Urology 12 (2020).